Neostigmina Braun (Neostigmine Methylsulfate)

Neostigmine methylsulfate, the active ingredient in Neostigmina Braun, is an anticholinesterase presented as a sterile solution for intramuscular, intravenous, and subcutaneous use. It is employed to improve neuromuscular transmission in myasthenia gravis, to reverse non‑depolarizing neuromuscular blockade after surgery, and to stimulate intestinal motility in postoperative ileus.

GNH USA supplies Neostigmina Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable and efficient logistics for global healthcare providers.

Neostigmine methylsulfate is used to enhance cholinergic transmission in several neuromuscular and gastrointestinal conditions.

Myasthenia gravis: improves muscle strength by increasing acetylcholine at the neuromuscular junction. Reversal of non-depolarizing neuromuscular blockade: restores muscle function after anesthetic agents. Postoperative ileus: stimulates intestinal motility to reduce recovery time.

Neostigmine methylsulfate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Increased salivation - Muscle twitching

Serious or Rare Side Effects: - Bradycardia - Bronchospasm - Cholinergic crisis

When using Neostigmina Braun, consider the following safety measures.

Renal impairment: adjust dose in patients with reduced kidney function. Cardiac conditions: monitor heart rate and rhythm due to risk of bradycardia. Respiratory disease: use cautiously in asthma or COPD because of bronchospasm risk. Concomitant anticholinergic drugs: avoid simultaneous use as they may counteract the effect. Hypersensitivity: discontinue if an allergic reaction occurs. Store at ambient temperature: keep in the original container, protect from moisture and light.

Neostigmina Braun can interact with several medicines; awareness helps prevent complications.

Major Interactions (Avoid): - Concurrent use with other anticholinesterases: risk of cholinergic excess. - Beta‑blockers: may potentiate bradycardia. - Digoxin: increased risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Non‑depolarizing muscle relaxants: additive reversal effect. - Aminoglycoside antibiotics: may interfere with neuromuscular transmission. - Anticholinergic agents (e.g., atropine): may diminish therapeutic effect. - Succinylcholine: potentiation of cholinergic activity.